ZA200904031B - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number: ZA200904031B
Authority: ZA; South Africa
Prior art keywords: chemical compounds; potency; phosphoramidate; enhanced; nucleoside
Prior art date: 2006-11-24

Application number

ZA200904031A

Other languages

English (en)

Inventor

Christopher Mcguigan

Plinio Perrone

Johan Neyts

Original Assignee

Univ Cardiff

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-24

Filing date

2009-06-10

Publication date

2010-04-28

2009-06-10 Application filed by Univ Cardiff filed Critical Univ Cardiff

2010-04-28 Publication of ZA200904031B publication Critical patent/ZA200904031B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Virology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ZA200904031A 2006-11-24 2009-06-10 Chemical compounds ZA200904031B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0623493.4A GB0623493D0 (en)	2006-11-24	2006-11-24	Chemical compounds

Publications (1)

Publication Number	Publication Date
ZA200904031B true ZA200904031B (en)	2010-04-28

Family

ID=37636469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200904031A ZA200904031B (en)	2006-11-24	2009-06-10	Chemical compounds

Country Status (26)

Country	Link
US (1)	US8658616B2 (xx)
EP (2)	EP2097434B1 (xx)
JP (1)	JP5271913B2 (xx)
KR (1)	KR20090114356A (xx)
CN (1)	CN101547932B (xx)
AT (1)	ATE512973T1 (xx)
AU (1)	AU2007323220B2 (xx)
CA (1)	CA2670328C (xx)
CO (1)	CO6230992A2 (xx)
CY (1)	CY1112254T1 (xx)
DK (1)	DK2097434T3 (xx)
EC (1)	ECSP099462A (xx)
ES (1)	ES2368012T3 (xx)
GB (1)	GB0623493D0 (xx)
IL (1)	IL198610A (xx)
MX (1)	MX2009005120A (xx)
MY (1)	MY145856A (xx)
NO (1)	NO20092399L (xx)
NZ (2)	NZ593712A (xx)
PL (1)	PL2097434T3 (xx)
PT (1)	PT2097434E (xx)
RU (1)	RU2464272C2 (xx)
SG (1)	SG171596A1 (xx)
SI (1)	SI2097434T1 (xx)
WO (1)	WO2008062206A2 (xx)
ZA (1)	ZA200904031B (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
BR0316363A (pt)	2002-11-15	2005-10-04	Idenix Cayman Ltd	Nucleosìdeos 2'-ramificado e mutação de flaviviridae
GB0623493D0 (en)	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7951789B2 (en)	2006-12-28	2011-05-31	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
AU2009277172B2 (en) *	2008-07-02	2014-05-29	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
NZ593648A (en)	2008-12-23	2013-09-27	Gilead Pharmasset Llc	Nucleoside phosphoramidates
NZ617066A (en)	2008-12-23	2015-02-27	Gilead Pharmasset Llc	Nucleoside analogs
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
BRPI1004575A2 (pt)	2009-01-09	2016-04-05	Inhibitex Inc	composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
PL3290428T3 (pl)	2010-03-31	2022-02-07	Gilead Pharmasset Llc	Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2644990T3 (es)	2010-03-31	2017-12-01	Gilead Pharmasset Llc	Síntesis estereoselectiva de principios activos que contienen fósforo
SG188497A1 (en) *	2010-09-22	2013-05-31	Alios Biopharma Inc	Substituted nucleotide analogs
GB201016855D0 (en) *	2010-10-06	2010-11-17	Nucana Biomed Ltd	Chemical compounds
PT3042910T (pt)	2010-11-30	2019-04-16	Gilead Pharmasset Llc	2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2691409B1 (en)	2011-03-31	2018-02-21	Idenix Pharmaceuticals LLC.	Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en)	2011-09-12	2016-08-02	Idenix Pharmaceuticals Llc	Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en)	2011-10-14	2013-04-18	Idenix Pharmaceuticals, Inc.	Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EP2852604B1 (en)	2012-05-22	2017-04-12	Idenix Pharmaceuticals LLC	3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en)	2012-05-22	2018-01-31	Idenix Pharmaceuticals LLC	3',5'-cyclic phosphate prodrugs for hcv infection
EP2852603B1 (en)	2012-05-22	2021-05-12	Idenix Pharmaceuticals LLC	D-amino acid compounds for liver disease
SG11201407336PA (en)	2012-05-25	2015-03-30	Janssen Sciences Ireland Uc	Uracyl spirooxetane nucleosides
EP2900682A1 (en)	2012-09-27	2015-08-05	IDENIX Pharmaceuticals, Inc.	Esters and malonates of sate prodrugs
AU2013329521B2 (en)	2012-10-08	2018-04-19	Centre National De La Recherche Scientifique	2'-chloro nucleoside analogs for HCV infection
US10723754B2 (en)	2012-10-22	2020-07-28	Idenix Pharmaceuticals Llc	2′,4′-bridged nucleosides for HCV infection
PT3235824T (pt)	2012-11-16	2019-05-30	NuCana plc	Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
US9211300B2 (en)	2012-12-19	2015-12-15	Idenix Pharmaceuticals Llc	4′-fluoro nucleosides for the treatment of HCV
US9309275B2 (en)	2013-03-04	2016-04-12	Idenix Pharmaceuticals Llc	3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en)	2013-03-13	2014-09-18	Idenix Pharmaceuticals, Inc.	Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en)	2013-04-01	2015-11-17	Idenix Pharmaceuticals Llc	2′,4′-fluoro nucleosides for the treatment of HCV
JP2016522172A (ja)	2013-04-12	2016-07-28	アキリオンファーマシューティカルズ，インコーポレーテッド	Ｈｃｖを治療するのに有用な重水素化されたヌクレオシドプロドラッグ
EP3004130B1 (en)	2013-06-05	2019-08-07	Idenix Pharmaceuticals LLC.	1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en)	2013-08-01	2015-02-05	Idenix Pharmaceuticals, Inc.	D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
NZ716840A (en)	2013-08-27	2017-06-30	Gilead Pharmasset Llc	Combination formulation of two antiviral compounds
CN104447923B (zh) *	2013-09-23	2018-03-30	中国药科大学	2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
WO2015161137A1 (en)	2014-04-16	2015-10-22	Idenix Pharmaceuticals, Inc.	3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
SMT201900489T1 (it)	2014-11-28	2019-11-13	NuCana plc	Nuovi derivati estere fosforammidato di 3'-deossiadenosina con amminoacidi in 2' e/o 5' come composti anticancro
AU2016229966B2 (en) *	2015-03-06	2018-09-27	Atea Pharmaceuticals, Inc.	Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en)	2016-07-14	2018-01-18	Atea Pharmaceuticals, Inc.	Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
ES2907874T3 (es)	2016-09-07	2022-04-26	Atea Pharmaceuticals Inc	Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
JP7066728B2 (ja)	2017-02-01	2022-05-13	アテアファーマシューティカルズ，インコーポレイテッド	Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
WO2019200005A1 (en)	2018-04-10	2019-10-17	Atea Pharmaceuticals, Inc.	Treatment of hcv infected patients with cirrhosis
WO2021173713A1 (en)	2020-02-27	2021-09-02	Atea Pharmaceuticals, Inc.	Highly active compounds against covid-19
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
WO2022040301A1 (en) *	2020-08-18	2022-02-24	University Of Southern California	Promoiety strategy to enhance drug activity
US12274700B1 (en)	2020-10-30	2025-04-15	Accencio LLC	Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
JP2024525164A (ja)	2021-06-17	2024-07-10	アテアファーマシューティカルズ，インコーポレイテッド	有利な抗ｈｃｖ併用療法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614504A (en)	1990-08-01	1997-03-25	The University Of South Florida	Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
GB9505025D0 (en)	1995-03-13	1995-05-03	Medical Res Council	Chemical compounds
JP4313847B2 (ja)	1995-04-21	2009-08-12	ユニヴァーシティオブサウスフロリダ	免疫賦活性イノシン一リン酸の５’−ヌクレオチダーゼ抵抗性誘導体およびその使用
WO1997021452A2 (en)	1995-12-14	1997-06-19	Advanced Magnetics, Inc.	Macromolecular prodrugs of nucleotide analogs
US5959100A (en)	1996-03-27	1999-09-28	Nexstar Pharmaceuticals, Inc.	Pyrimidine nucleosides as therapeutic and diagnostic agents
AU3363499A (en)	1998-03-27	1999-10-18	George W. Griesgraber	Nucleosides with antiviral and anticancer activity
US7144874B2 (en)	2002-10-25	2006-12-05	Parker Hughes Institute	Aryl phosphate derivatives of d4T having activity against resistant HIV strains
US6030957A (en)	1998-06-29	2000-02-29	Wayne Hughes Institute	Aryl phosphate derivatives of d4T having anti-HIV activity
GB9821058D0 (en) *	1998-09-28	1998-11-18	Univ Cardiff	Chemical compound
AU1916201A (en)	1999-11-08	2001-06-06	Origenix Technologies, Inc.	Combinatorial library synthesis and pharmaceutically active compounds produced thereby
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
AU6348401A (en)	2000-05-26	2001-12-11	Novirio Pharmaceuticals Ltd	Methods of treating hepatitis delta virus infection with beta-l-2'- deoxy-nucleosides
IL153020A0 (en)	2000-05-26	2003-06-24	Idenix Cayman Ltd	Methods and compositions for treating flaviviruses and pestiviruses
ATE325806T1 (de)	2000-10-04	2006-06-15	Santaris Pharma As	Verbesserte synthese von purin-blockierten nukleinsäure-analoga
MY141789A (en) *	2001-01-19	2010-06-30	Lg Chem Investment Ltd	Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
EP1539188B1 (en)	2001-01-22	2015-01-07	Merck Sharp & Dohme Corp.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7563618B2 (en)	2001-03-23	2009-07-21	Geron Corporation	Oligonucleotide conjugates
EP1404694A1 (en)	2001-06-21	2004-04-07	Glaxo Group Limited	Nucleoside compounds in hcv
US6962991B2 (en)	2001-09-12	2005-11-08	Epoch Biosciences, Inc.	Process for the synthesis of pyrazolopyrimidines
JP2005519916A (ja)	2001-12-14	2005-07-07	フアーマセツト・リミテツド	ウィルス感染治療用ｎ４−アシルシトシンヌクレオシド類
WO2003051899A1 (en)	2001-12-17	2003-06-26	Ribapharm Inc.	Deazapurine nucleoside libraries and compounds
WO2003061385A1 (en)	2002-01-17	2003-07-31	Ribapharm Inc.	Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
WO2003062256A1 (en)	2002-01-17	2003-07-31	Ribapharm Inc.	2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003062255A2 (en)	2002-01-17	2003-07-31	Ribapharm Inc.	Sugar modified nucleosides as viral replication inhibitors
JP2005522443A (ja)	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
CN1863538A (zh) *	2002-09-30	2006-11-15	健亚生物科技公司	用于治疗c型肝炎病毒感染的核苷衍生物
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
WO2006012078A2 (en)	2004-06-24	2006-02-02	Merck & Co., Inc.	Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7261853B2 (en) *	2004-07-16	2007-08-28	Eagle Mold Company	Decelerated ejector pin system and method for operating the same
JP2008517912A (ja)	2004-10-21	2008-05-29	メルクエンドカムパニーインコーポレーテッド	ＲＮＡ依存性ＲＮＡウイルス感染治療用フッ素化ピロロ［２，３−ｄ］ピリミジンヌクレオシド
CA2589935A1 (en)	2004-12-09	2006-06-15	Regents Of The University Of Minnesota	Nucleosides with antiviral and anticancer activity
GB0505781D0 (en)	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
US7405204B2 (en)	2005-04-25	2008-07-29	Genelabs Technologies, Inc.	Nucleoside compounds for treating viral infections
WO2006121820A1 (en) *	2005-05-05	2006-11-16	Valeant Research & Development	Phosphoramidate prodrugs for treatment of viral infection
WO2007020193A2 (en)	2005-08-15	2007-02-22	F. Hoffmann-La Roche Ag	Antiviral phosphoramidates of 4 ' -substituted pronucleotides
WO2007095269A2 (en)	2006-02-14	2007-08-23	Merck & Co., Inc.	Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
GB0623493D0 (en)	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
EP2120565B1 (en)	2006-12-20	2012-11-28	Merck Sharp & Dohme Corp.	Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
AU2007342367B2 (en)	2007-01-05	2012-12-06	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
WO2008104408A2 (en)	2007-02-27	2008-09-04	K. U. Leuven Research & Development	Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs

2006
- 2006-11-24 GB GBGB0623493.4A patent/GB0623493D0/en not_active Ceased
2007
- 2007-11-23 KR KR1020097013078A patent/KR20090114356A/ko not_active Ceased
- 2007-11-23 US US12/516,253 patent/US8658616B2/en not_active Expired - Fee Related
- 2007-11-23 AU AU2007323220A patent/AU2007323220B2/en not_active Ceased
- 2007-11-23 PT PT07824684T patent/PT2097434E/pt unknown
- 2007-11-23 ES ES07824684T patent/ES2368012T3/es active Active
- 2007-11-23 RU RU2009123104/04A patent/RU2464272C2/ru not_active IP Right Cessation
- 2007-11-23 AT AT07824684T patent/ATE512973T1/de active
- 2007-11-23 WO PCT/GB2007/004480 patent/WO2008062206A2/en not_active Ceased
- 2007-11-23 JP JP2009537699A patent/JP5271913B2/ja not_active Expired - Fee Related
- 2007-11-23 EP EP07824684A patent/EP2097434B1/en not_active Not-in-force
- 2007-11-23 NZ NZ593712A patent/NZ593712A/xx not_active IP Right Cessation
- 2007-11-23 NZ NZ577152A patent/NZ577152A/en not_active IP Right Cessation
- 2007-11-23 PL PL07824684T patent/PL2097434T3/pl unknown
- 2007-11-23 DK DK07824684.0T patent/DK2097434T3/da active
- 2007-11-23 CN CN200780045190.7A patent/CN101547932B/zh not_active Expired - Fee Related
- 2007-11-23 MY MYPI20091944A patent/MY145856A/en unknown
- 2007-11-23 EP EP11169876A patent/EP2412717A1/en not_active Withdrawn
- 2007-11-23 CA CA2670328A patent/CA2670328C/en not_active Expired - Fee Related
- 2007-11-23 SI SI200730726T patent/SI2097434T1/sl unknown
- 2007-11-23 MX MX2009005120A patent/MX2009005120A/es active IP Right Grant
- 2007-11-23 SG SG201102856-0A patent/SG171596A1/en unknown
2009
- 2009-05-06 IL IL198610A patent/IL198610A/en not_active IP Right Cessation
- 2009-06-10 ZA ZA200904031A patent/ZA200904031B/xx unknown
- 2009-06-19 CO CO09064160A patent/CO6230992A2/es active IP Right Grant
- 2009-06-23 EC EC2009009462A patent/ECSP099462A/es unknown
- 2009-06-24 NO NO20092399A patent/NO20092399L/no not_active Application Discontinuation
2011
- 2011-09-13 CY CY20111100875T patent/CY1112254T1/el unknown

Also Published As

Publication number	Publication date
JP5271913B2 (ja)	2013-08-21
RU2009123104A (ru)	2010-12-27
CY1112254T1 (el)	2015-12-09
CN101547932B (zh)	2014-04-16
WO2008062206A8 (en)	2011-11-10
SI2097434T1 (sl)	2011-10-28
PT2097434E (pt)	2011-09-07
NO20092399L (no)	2009-06-24
PL2097434T3 (pl)	2011-11-30
IL198610A0 (en)	2010-02-17
NZ577152A (en)	2012-01-12
AU2007323220A1 (en)	2008-05-29
EP2412717A1 (en)	2012-02-01
RU2464272C2 (ru)	2012-10-20
US20110124592A1 (en)	2011-05-26
EP2097434B1 (en)	2011-06-15
AU2007323220B2 (en)	2012-09-06
WO2008062206A2 (en)	2008-05-29
ECSP099462A (es)	2009-08-28
CO6230992A2 (es)	2010-12-20
MX2009005120A (es)	2009-09-23
SG171596A1 (en)	2011-06-29
IL198610A (en)	2013-11-28
US8658616B2 (en)	2014-02-25
JP2010510301A (ja)	2010-04-02
NZ593712A (en)	2012-09-28
DK2097434T3 (da)	2011-08-29
EP2097434A2 (en)	2009-09-09
WO2008062206A3 (en)	2008-07-10
GB0623493D0 (en)	2007-01-03
CN101547932A (zh)	2009-09-30
KR20090114356A (ko)	2009-11-03
ATE512973T1 (de)	2011-07-15
ES2368012T3 (es)	2011-11-11
CA2670328A1 (en)	2008-05-29
MY145856A (en)	2012-04-30
CA2670328C (en)	2013-09-24

Publication	Publication Date	Title
ZA200904031B (en)	2010-04-28	Chemical compounds
NZ597544A (en)	2013-04-26	Modified 4'-nucleosides as antiviral agents
MY128463A (en)	2007-02-28	4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
JO2403B1 (en)	2007-06-17	Nickeloside derivatives antiviral
TW200630344A (en)	2006-09-01	Tetracyclic indole derivatives as antiviral agents
PL366726A1 (en)	2005-02-07	4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
WO2007020193A3 (en)	2007-10-25	Antiviral phosphoramidates of 4 ' -substituted pronucleotides
EP2041159B8 (en)	2012-02-22	Macrocyclic compounds as antiviral agents
WO2006027628A3 (en)	2006-05-04	Naphthalimide derivatives as antiviral agents
PL1719773T3 (pl)	2009-08-31	Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV
NO20023852L (no)	2002-10-09	Nukleosidanaloger med karboksamidin-modifisert bisyklisk base
WO2007070598A3 (en)	2008-10-30	Nucleotide and oligonucleotide prodrugs
EA200900156A1 (ru)	2009-06-30	Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
MX2009012613A (es)	2010-04-21	Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
WO2005084192A3 (en)	2006-05-11	Novel 2’-c-methyl nucleoside derivatives
WO2008056264A3 (en)	2008-10-30	Novel nucleotide analogues as percursor molecules for antivirals
WO2005084315A3 (en)	2007-02-08	Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
WO2007092558A3 (en)	2007-12-27	Sulfonamide derivatives to treat infection with hepatitis c virus
TH126308A (th)	2013-08-19	สารประกอบ และองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัส